GSK Abandons Plans For Anemia Drug Launch In Europe

Looking To Avoid Mistakes Of The Past

 
• By Andrew McConaghie

GSK is cutting its losses by not launching its anemia drug daprodustat in Europe, something it hopes will make sense to investors who want to see it avoid the underwhelming ‘me too’ launches of the past.

EMA
The EMA's medicines committee recommended daprodustat, but GSK withdrew its filing because of limited commercial potential. • Source: Getty Images

More from Business

More from Scrip